( The study was terminated because the first Phase 3 did not demonstrate efficacy on the co-primary endpoints. The known safety profile remained unchanged. )
Study NCT01524887
Information provided by Baxter Healthcare Corporation
First Received on January 20, 2012.
Last Updated on May 19, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
